The health and biomedicine ecosystem in Catalonia is maturing and there are more and more companies that have experienced the whole business cycle through to success. The Study on investment in the Biomedical industry compiled by CataloniaBio & HealthTech and EY shows that 32 licensing agreements were signed in 2017 and 7% of biopharma and 19% of medtech companies have products on the market.

At various points in the lifecycle of a company, entrepreneurs ask themselves the following questions: What model best suits my company? Should I out-license? Sell the company? Or market the product in different markets? The answer to these questions conditions the whole strategy. What are the key factors for success in each model? We’ll find out from those who have lived it at the next Lessons Learned session on 4 July at the Barcelona Science Park, with experts sharing their knowledge and points of view in a dynamic, participative debate.

Moderator:

Judit Anido, general director of Mosaic Biomedicals and board member of CataloniaBio & HealthTech

Speakers:

• Julio Castro, general director of Palobiofarma
• Jordi Carrera, Vicepresident, Syndromic Insights (Business Area Molecular Diagnostics) of QIAstat-Dx
• Lluís Chico, CEO of NEOS Surgery

PROGRAM

For: entrepreneurs, executives and professionals of biotech, MedTech and digital health companies, as well as TTO managers.

Capacity: 40 spots

Registration fees:

• Non-members: €50 (VAT included). You will be invoiced €50/person.
• CataloniaBioHT members: two free spots.

Related news:

• Report: "Catalan biomedical companies enter the promised land"
• Photo gallery

What are Lessons Learned?

The Lessons Learned sessions, which kicked off in 2014 promoted by CataloniaBio & HealthTech, are a knowledge forum for professionals in the health and biomedicine arena to share experiences and reflections with experts on various strategic areas to boost the competitiveness of companies. The Lessons Learned sessions are also a great opportunity for networking.